MDSpire - Takeaway
From the Journals

CAR-Engineered Astrocytes in Alzheimer’s Models

Preclinical findings show engineered astrocytes reduce amyloid buildup in mouse models and demonstrate a potential therapeutic approach

  • March 25, 2026

  • 2 min

Share

  • 1

    - Development of CAR-expressing astrocytes for Alzheimer's. - Targeting and clearing amyloid-β in vitro and in mouse models. - Non-invasive delivery via adeno-associated viral vectors. - Self-sustaining system reduces safety risks associated with monoclonal antibodies. - Variation in CAR designs yields different biological impacts. - Need for further studies to ensure safety and human applicability.

Original Source(s)

CAR-Engineered Astrocytes in Alzheimer’s Models

  • March 25, 2026

Related Content

Tau Biomarker Expands Beyond Alzheimer’s

Study finds elevated phosphorylated tau in AL and ATTR amyloidosis, suggesting a potential blood biomarker for amyloid-related neuropathy

  • March 25, 2026

  • 3 min
Researchers Propose TMD Definition for GBD

Consensus description may support inclusion in Global Burden of Disease estimates.

ALS Trial Tests Celecoxib–Ciprofloxacin Combination

Dual-drug therapy showed signals of slower disease progression and reduced complications in patients with ALS.